Print Page | Close Window

Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$63.03

0.00 (0.00%)

High$63.75
Low$61.39
Volume0
Market Cap$8,981,376,398

03/22/17  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

FDA Lifts Clinical Hold on Seattle Genetics’ Phase 1 Trials of Vadastuximab Talirine 03/06/17

Read more

Seattle Genetics to Present at Upcoming Investor Conferences 03/01/17

Read more

Events

Barclays Global Healthcare Conference 201703/15/17 10:45 a.m. ETView eventCowen and Company 37th Annual Health Care Conference03/08/17 10:40 a.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
© 2014 Seattle Genetics, Inc.